Kornimate/medical-research-clean huggingface dataset:
biomarkers in exhaled breath from asthmatic patients

Conditions: Asthma

Summary: this study will look for a relationship between asthma and factors released from the lungs in exhaled breath. if a relationship can be established, the identified factors may be used as biomarkers to predict episodes of increased asthma symptoms so that medications can be given to prevent the onset of an asthma attack. healthy volunteers and people who have had asthma for at least 1 year may be eligible for this study. candidates must be between 18 and 75 years of age. participants undergo blood tests and breathing tests. for the latter, participants breathe into a machine before and after inhaling an asthma medication called albuterol. the machine measures the volume of air the subject can breathe out. participants also provide a sample of exhaled breath by breathing normally for up to 30 minutes while wearing a mask devised for the procedure. pulse rate, oxygen saturation and wheezing are monitored during the breath collection.

asthma is a major public health problem that is associated with significant morbidity and mortality. patients at increased risk for asthma decompensations include those with severe asthma that is refractory to therapy, as well as patients with poorly controlled disease due to inadequate treatment. the aim of this exploratory specimen procurement protocol is to develop a non-invasive method for the detection of asthma-specific biomarkers in exhaled breath condensates (ebc) utilizing a novel collection device that was engineered at the johns hopkins university applied physics laboratory. biomarkers in ebc will be identified by mass spectroscopy. we propose that the identification of biomarkers in ebc that correlate with airway inflammation and disease activity may be used to guide therapy and prevent exacerbations in asthmatic patients.

Eligibility criteria:
* inclusion criteria - asthma: patients will be between 18 and 75 years of age, male or female, with a diagnosis of asthma for at least one year. oxygen saturation on room air greater than or equal to 92 percent. exclusion criteria - asthma: diagnosis of a pulmonary disorder other than asthma (for example: chronic bronchitis, emphysema, cystic fibrosis, bronchiectasis, sarcoidosis, hiv-related lymphocytic airway inflammation). cigarette smoking within the past 3 months or a prior history of greater than 10 cumulative pack-years. history of coronary artery disease. inclusion criteria healthy volunteers: research volunteers will be between 18 and 75 years of age, male or female. oxygen saturation on room air greater than or equal to 92 percent. exclusion criteria healthy volunteers: same as the asthmatic exclusion criteria plus a history of asthma. reversible airflow obstruction (increase in fev (1) by 12 percent and 200 cc after inhaled beta 2-agonist)

Keywords: asthma biomarker exhaled breath condensate cytokine healthy volunteer hv
kinesiophobia and pressure sore risk after bariatric surgery.

Conditions: Kinesiophobia; Pressure Sore; Emotional Freedom Technique; Complementary Therapies; Bariatric Surgery

Summary: the aim of this study was to investigate the effect of emotional freedom technique on kinesiophobia and the risk of developing pressure sores in patients undergoing obesity surgery. the hypotheses of the study are as follows: h1-0: emotional liberation technique has no effect on kinesiophobia in patients undergoing bariatric surgery. h1-1: emotional liberation technique has a positive effect on kinesiophobia in patients undergoing bariatric surgery. h2-0: emotional liberation technique has no effect on the risk of developing pressure ulcers in patients undergoing bariatric surgery. h2-1: emotional liberation technique has a positive effect on the risk of developing pressure ulcers in patients undergoing bariatric surgery.

intervention group: after the pre-test application (personal introduction form, tampa kinesiophobia scale and braden pressure sore risk assessment scale) eft was applied to the patients when they were stable before the bariatric surgery and they were taught to do it on their own. after the bariatric surgery, the patients were asked to do 1 session of eft and were accompanied. after the application, the patients were applied post-tests (tampa kinesiophobia scale and braden pressure sore risk assessment scale). eft training was given by a researcher who has a certificate in the field. control group patients were administered pre-tests (personal introduction form, tampa kinesiophobia scale and braden pressure sore risk assessment scale) at a stable time before bariatric surgery. post-tests (tampa kinesiophobia scale and braden pressure sore risk assessment scale) were administered to patients after bariatric surgery at a stable time. after the post-tests, eft was administered to patients in the control group.

Eligibility criteria:
inclusion criteria: 1. being 18 years of age or older 2. having had obesity surgery 3. not having any visual or auditory problems 4. not having any psychiatric problems. exclusion criteria: 1. not accepting to participate in the study or wanting to leave 2. being under 18 years of age.

Keywords: pressure sore kinesiophobia emotional freedom technique
tanezumab in osteoarthritis of the hip

Conditions: Arthritis; Osteoarthritis; Osteoarthritis, Hip

Summary: the purpose of this study is to test the efficacy and safety of 3 doses of tanezumab in osteoarthritis of the hip in patients


Eligibility criteria:
inclusion criteria: * osteoarthritis of the hip according to acr criteria with kellgren-lawrence x-ray grade of 2 * unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for hip injections, arthroplasty or replacement surgery * pain level and function levels as required by the protocol at screening and baseline * willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study * must agree to the contraceptive requirements of the protocol if applicable * must agree to the treatment plan, scheduled visits, and procedures of the protocol exclusion criteria: * pregnancy * bmi greater than 39 * other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

Keywords: monoclonal antibody rn624 pf-04383119 nerve growth factor anti-nerve growth oa
td-1211 single-dose study in elderly and young healthy subjects

Conditions: Constipation

Summary: the purpose of this study is to measure the way in which td-1211 is absorbed and eliminated by the body and to evaluate whether it is safe and well tolerated.


Eligibility criteria:
inclusion criteria: * for the elderly cohort, nonsmoking 65 to 85 years, inclusive. for the young cohort, nonsmoking 18 to 45 years, inclusive. * body mass index (bmi) should be 18 to 36 kg/m2, inclusive. * at screening, sitting or supine heart rate of 50 to 100 beats per minute and sitting or supine systolic and diastolic blood pressure of 90 to 150 mm hg and 50 to 90 mm hg, respectively (2 of 3 measurements) * subjects with mild, chronic, stable disease (e.g., controlled hypertension, non-insulin-dependent diabetes, arthritis) may be enrolled if deemed medically acceptable by the investigator * negative for hepatitis b virus, hepatitis c virus, and human immunodeficiency virus antibody within the last 3 months * no clinically relevant abnormalities in laboratory evaluations exclusion criteria: * history or presence of clinically significant respiratory, gastrointestinal, renal, hepatic, endocrine, hematological, neurological (including chronic headache, current or prior psychiatric disease/condition, stroke), cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, or dermatological disorders. subjects with mild, chronic, stable disease (e.g., controlled hypertension, controlled hypercholesterolemia, non insulin-dependent diabetes, osteoarthritis) may be enrolled if condition is well controlled and not anticipated to interfere with the objectives of the study. * any clinically significant abnormal ecg (electrocardiogram). * participation in another clinical trial of an investigational drug or medical device within 60 days. * donation of ≥500 ml blood, or equivalent, within 8 weeks prior to admission day. * any other condition that, in the opinion of the investigator, would confound or interfere with evaluation of safety, tolerability, or pk of the investigational drug or prevent compliance with the study protocol.

Keywords: opioid induced constipation constipation
influencing factors and their approach of kinesiophobia in patients with traumatic fractures

Conditions: Traumatic Fracture

Summary: this study aims to investigate the relationship between kinesiophobia and pain catastrophizing, as well as the relationship between pain catastrophizing and pain level, anxiety and depression, self-efficacy and psychological resilience in patients with traumatic fractures, and to explain the approach and effect relationship between kinesiophobia and these variables.

at present, there are few studies on kinesiophobia in patients with traumatic fractures. this study adopts structural equation model to analyze the current situation of kinesiophobia in patients with traumatic fractures, and explores the effect of pain level, pain catastrophizing, anxiety and depression, self-efficacy and psychological resilience on kinesiophobia in patients with traumatic fractures, which provides a scientific basis for predicting the occurrence of kinesiophobia in patients with traumatic fractures and developing intervention plans.

Eligibility criteria:
inclusion criteria: * patients who were diagnosed as fractures due to accidental trauma and were diagnosed by x-rays and clinicians and required surgical treatment. * age 18 and above. exclusion criteria: * those with a history of chronic pain (pain persisting or indirectly persisting for more than 3 months). * those who have serious postoperative complications (such as deep vein thrombosis, infection, etc.) and need other treatment or transfer to another department. * people with physical disability or abnormal muscle strength before injury. * those who have a history of mental illness or who have taken anti-anxiety, depression drugs, or cognitive impairment within one month. * patients undergoing emergency surgery on the day of admission. * those who cannot communicate normally due to physical or psychological barriers.

Keywords: traumatic fracture kinesiophobia pain catastrophizing anxiety depression self-efficacy psychological resilience
effect of antibiotic rotation in the icu on the prevalence of antibiotic resistant gram-negative colonisation

Conditions: Infections

Summary: the saturn icu-trial studies the effect of antibiotic rotation on the prevalence of antibiotic resistant gram-negative colonisation.

antibiotic rotation has been previously studied with varied results. the theory behind antibiotic rotation is that intermittently changing antibiotic classes will reduce the ecological selective pressure that drives the emergence of antibiotic resistance. this study compares the effect of 2 types of antibiotic rotation on gram-negative colonisation in the icu and also compares both interventions with standard care. the two interventions apply to the empiric treatment and are: 1) "fast" rotation, i.e. every other patient another class and 2) "slow" rotation, i.e. every other 1.5month another preferred class for empiric gram-negative antibiotic therapy.

Eligibility criteria:
inclusion criteria: * there are at least 8 beds, with an average bed-occupancy of 80%; all of which have capacity for mechanical ventilation. * the icu can adhere to the selected antibiotics for empiric treatment of infections. * there is an operational digital patient-information system, from which data can be extracted and delivered in a pre-defined format. specifically an automated process for digital data-collection regarding microbiological culture-results (from swabs and bacteraemias), antibiotic prescription and patient demographics and illness severity-scores. * colonization with esbl or resistance for any of the antibiotic groups is endemic, with proportions of icu-acquired bacteraemias used as a proxy. therefore, the investigators prefer proportions of amrb infection in the period 2008-2009 to be: esbl resistance among gnb 1 to 10% piperacillin/tazobactam among gnb 1 to10% carbapenem resistance among klebsiella pneumoniae less than 5% * have the ability of at least one dedicated infection control hcw available for 0,2fte, for patient monitoring, compliance monitoring and instruction of hcws regarding interventions. in the following this person will be called "research-nurse" or "rn". * can store screening-cultures at -70ºc * can facilitate transport through a umcu courier. * there is written approval for the study from the institution's irb with a waiver for patient informed consent. * a signature page is signed by the daily management of the candidate-icu by both icu physician and director and the icu nursing-director and presented to the umcu, indicating willingness to enroll the candidate-icu in the study. exclusion criteria: icus planning to introduce, during the saturn trial period, any major diagnostic- or intervention program that will affect amrb ecology\* * burn units; due to the specific nature of the care provided and the patients admitted. * cardiothoracic surgery units; because of the expected small number of patients admitted for three days or more. * paediatric and neonatal icus.

Keywords: antibiotic rotation cycling mixing gram-negative eu multi center multi centre cluster randomized trial cross over
prognostic value of plasma thrombospondin-1 levels after acute intracerebral hemorrhage

Conditions: Cerebral Hemorrhage

Summary: the current study was designed to investigate the change of plasma thrombospondin-1 levels and assess the prognostic predictive effect of plasma thrombospondin-1 levels in the patients with acute intracerebral hemorrhage.

thrombospondin-1 acts as an anti-angiogenic factor and its expression in rat brain is upregulated after intracerebral hemorrhage. the current study was designed to investigate the change of plasma thrombospondin-1 levels and assess the prognostic predictive effect of plasma thrombospondin-1 levels in the patients with acute intracerebral hemorrhage. about 110 patients will be recruited. all blood samples from the patients at admission were collected. thrombospondin-1 levels in plasma were measured using sandwich immunoassays. the patients will be followed up till 6 months after intracerebral hemorrhage. the relationships between plasma thrombospondin-1 levels and 1-week mortality, 6-month mortality, 6-month overall survival, 6-month unfavorable outcome (modified rankin scale score \>2) and disease severity reflected by hematoma volume and national institutes of health stroke scale score were assessed using multivariate analysis. it is proposed that elevated plasma thrombospondin-1 levels are independently associated with disease severity and clinical outcomes. it will be suggested thrombospondin has potential to be a good prognostic biomarker of intracerebral hemorrhage.

Eligibility criteria:
inclusion criteria: * acute spontaneous basal ganglia hemorrhage admitted to the jinhua people's hospital within the first 24 h from stroke. exclusion criteria: * previous ischemic or hemorrhagic stroke, severe head trauma, use of antiplatelet or anticoagulant medication, presence of other prior systemic diseases including autoimmune diseases, uremia, liver cirrhosis, malignancy, and chronic heart or lung disease, recent infection (within a month), a surgical procedure and missing of follow-up.
effect of enhanced feedback to hospitals in an emerging clinical information network

Conditions: Pneumonia

Summary: a cluster randomised pragmatic trial will be conducted within an emerging clinical information network composed of 12 kenyan county hospitals. hospitals will be randomised to an enhanced feedback intervention delivered over a nine-month period and compared to standard feedback. the trial to be implemented during a phase of implementing change in guideline recommendations for pneumonia will assess the impact of enhanced feedback on hospital uptake of the revised pneumonia treatment recommendations.

the international guidelines for the classification and treatment of childhood pneumonia were revised recently and in kenya the national guidelines changed in february 2016. we designed an enhanced feedback intervention aimed at improving uptake of the revised pneumonia treatment policy within a clinical network of 12 kenyan county referral hospitals. hospitals were randomized to receive either enhanced feedback (n = 6 hospitals) or standard feedback (n = 6 hospitals) delivered over a six-month period following nationwide pneumonia treatment policy change. the primary outcome is the proportion of all pneumonia admissions (fulfilling criteria for treatment with oral amoxicillin) who are correctly classified and treated using new guideline recommendations. the proportion of treatment change from oral amoxicillin to alternative antibiotics for pneumonia (considered a proxy measure of treatment failure) will be reported as a secondary outcome.

Eligibility criteria:
inclusion criteria: * children aged 2 to 59 months admitted to participating network hospitals with who pneumonia diagnosis eligible for treatment with oral amoxicillin exclusion criteria: * children aged 2 to 59 months with who pneumonia diagnosis and co-morbid illnesses requiring intravenous antibiotic treatment including severe acute malnutrition, bacteraemia, meningitis, or * children presenting with pneumonia and tuberculosis or cough lasting more than 2 weeks, or severe malaria

Keywords: feedback pneumonia quality of care
effects of myofascial release on pain, disability and electromyography of erector spinae in chronic low back pain

Conditions: Low Back Pain; Disability; Motor Activity; Range of Motion

Summary: the purpose of this study is to determine whether myofascial release techniques are effective in the improvement of pain, disability and electromyography response of lumbar muscles in patients with chronic low back pain.


Eligibility criteria:
inclusion criteria: * low back pain for more than 3 months exclusion criteria: * vertebra fractures * systemic disease (spondylitis, neoplasia, infectious, vascular, endocrine or metabolic disorders) * spinal surgery * advanced lumbar instability * osteoporosis (in advanced stage) * degenerative articular disease * acute soft tissue inflammation * rheumatoid arthritis * osteomyelitis * neuromuscular disease * lower limb musculoskeletal injuries * radiculopathy * cauda equine syndrome * myelopathy * stenosis * structural spine deformity (kyphoscoliosis...) * pregnancy * abundant menstruation * iud carrier * mental disease * dermatologic disease * skin sensitivity * aneurysma * corticosteroids treatment * anticoagulant therapy * hypertension * diabetes * hemophilia * leucemia * rejection to manual contact

Keywords: lumbar region pain fascia electromyography goniometry
a study to assess the effect of qaw039 in non-atopic asthmatic patients

Conditions: Asthma

Summary: the purpose of the study was to assess the clinical effect of qaw039 in non-atopic asthmatics taking low dose inhaled corticosteroid (ics) as background therapy.

this was a multi-centre, randomised, placebo-controlled, double blind, 3-arm study designed to compare the efficacy and safety of a once daily dose of qaw039 with placebo in non-atopic and atopic asthmatics both inadequately controlled despite receiving a low dose ics background therapy, over a 12 week treatment period. efficacy and safety of a once daily dose of qaw039 was also compared with an increased dose of ics in atopic asthmatics taking low dose ics as background therapy.

Eligibility criteria:
inclusion criteria: * written informed consent must be obtained before any assessment is performed * patients with a diagnosis of persistent asthma (according to global initiative for asthma 2011) for a period of at least 6 months prior to screening * patients with a pre-bronchodilator forced expiratory volume in one second (fev1) value of 40% to 80% of individual predicted value at screening and prior to treatment * an asthma control questionnaire score ≥ 1.5 prior to treatment * demonstration of reversible airway obstruction exclusion criteria: * pregnant or nursing (lactating) women * acute illness other than asthma at the start of the study * patients with clinically significant laboratory abnormalities at screening * patients with clinically significant condition which may compromise subject safety or interfere with study evaluation * use of other investigational drugs at the time of enrollment
penehyclidine and postoperative nausea and vomiting after bimaxillary surgery

Conditions: Penehyclidine; Postoperative Nausea and Vomiting; Bimaxillar Surgery

Summary: postoperative nausea and vomiting (ponv) are common complications after surgery. patients undergoing orthognathic surgery are reported to have a high rate of ponv, especially those undergoing bimaxillary surgery. activation of cholinergic system plays an important role in the development of ponv. penehyclidine is an muscarinic antagonists which selectively block m1 and m3 receptors and is commonly used to decrease oral secretion. the purpose of this retrospective cohort study is to investigate whether use of penehyclidine is associated with a reduced risk of ponv in patients undergoing bimaxillary surgery.

postoperative nausea and vomiting (ponv) are one of the most frequent complications after surgery, and are associated with patients' dissatisfaction after anesthesia and surgery. orthognathic surgery is widely performed for the correction of dentofacial deformities. ponv is common after orthognathic surgery. despite of improved anti-emetic prophylaxis, patients undergoing orthognathic surgery are reported to have a high incidence of ponv, especially those after bimaxillary surgery. it is known that activation of central cholinergic system plays an important role in the development of ponv. muscarinic antagonists such as scopolamine can block muscarinic receptors in the cerebral cortex and produce anti-emetic effects. penehyclidine is a new muscarinic antagonists which selectively block m1 and m3 receptors. it has fewer adverse effects compared with other anticholinergics. the purpose of this retrospective cohort study is to investigate whether use of penehyclidine is associated with a reduce risk of ponv in patients undergoing bimaxillary surgery.

Eligibility criteria:
inclusion criteria: * age ≥16 years; * underwent elective bimaxillary surgery under general anesthesia. exclusion criteria: * age \<16 years; * missing data.

Keywords: penehyclidine postoperative nausea and vomiting bimaxillary surgery